Currently out of the existing stock ratings of Asthika Goonewardene, 156 are a BUY (90.7%), 16 are a HOLD (9.3%).

Asthika Goonewardene

Work Performance Price Targets & Ratings Chart

Analyst Asthika Goonewardene, currently employed at TRUIST, carries an average stock price target met ratio of 48.85% that have a potential upside of 41.72% achieved within 176 days.

Asthika Goonewardene’s has documented 327 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on STRO, Sutro Biopharma at 11-Jun-2026.

Wall Street Analyst Asthika Goonewardene

Analyst best performing recommendations are on SMMT (SUMMIT THERAPEUTICS PLC).
The best stock recommendation documented was for SMMT (SUMMIT THERAPEUTICS PLC) at 4/10/2025. The price target of $35 was fulfilled within 14 days with a profit of $14.85 (73.7%) receiving and performance score of 52.64.

Average potential price target upside

of $233.67 (81.78%) on NXTC (NEXTCURE ).
of $90.54 (46.21%) on ACET (ADICET BIO).
of $68.3 (68.81%) on STRO (SUTRO BIOPHARMA).

ALLO Allogene Therapeutics CELU Celularity CGEN Compugen EXEL Exelixis GMAB Genmab AS HARP Harpoon Therapeutics IGMS IGM Biosciences IOVA Iovance Biotherapeutics STRO Sutro Biopharma TCRR Tcr2 Therapeutics HOOK Hookipa Pharma NXTC NextCure AUTL Autolus Therapeutics Ltd TIL Instil Bio SGEN Seagen ACET Adicet Bio ACLX Arcellx IMGN ImmunoGen MRSN Mersana Therapeutics CRBU Caribou Biosciences GILD Gilead Sciences MRUS Merus BV CRGX CARGO Therapeutics, Common Stock BNTX BioNTech SE LEGN Legend Biotech Corp RCUS Arcus Biosciences SMMT Summit Therapeutics PLC

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Robert Burns (HC WAINWRIGHT)